Document is current

Article History

Accepted: 13 April 2021

First Online: 28 May 2021

Competing interests

: H.W. receives honoraria for acting as a member of Scientific Advisory Boards for Biogen, Evgen, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Roche Pharma, and Sanofi-Aventis and receives speaker honoraria and travel support from Alexion, Biogen, Cognomed, F. Hoffmann-La Roche, Gemeinnützige Hertie-Stiftung, Merck Serono, Novartis, Roche Pharma, Genzyme, Teva, and WebMD Global. He is also a paid consultant for Abbvie, Actelion, Biogen, IGES, Johnson & Johnson, Novartis, Roche, Sanofi-Aventis and the Swiss Multiple Sclerosis Society. His research is funded by Biogen, GlaxoSmithKline GmbH, Roche Pharma AG, and Sanofi-Genzyme. C.C.G. has received speaker honoraria from Bayer Health Care, MyLan and Genzyme, and travel expenses for attending meetings from Bayer Health Care, Biogen, Euroimmun, Genzyme, MyLan and Novartis Pharma. She recieves research funding from Biogen, Roche, and Novartis. R.L. has received grant support from BMS, GlaxoSmithKline and Pierre Fabre. He has received speaker or scientific board honoraria from Biogen, Novartis, Sanofi-Genzyme, and Servier and currently has grants from ANR, ARSEP, Cancer Research Institute, French Cancer research foundation (ARC), ERA-Net Narcomics, GlaxoSmithKline, Rare Diseases Foundation, and RHU BETPSY.